Hugel (145020) Investor Day 2026 presentation summary

Vision and commitments

• Strategy remains focused on evolving from a Korean leader into a global medical aesthetics leader; 2028 revenue target KRW 900bn, with 30% contribution from the US.

• Target a fully direct US model by mid-2027 and 14% US market share by 2030; transition the current hybrid model to a contract sales organization (CSO).

• Reported progress includes No. 1 toxin in Korea for 10 consecutive years, China market share above 20%, Brazil on track for 20% after re-entry, and Europe targeting high-single-digit share.

US market and go-to-market

• US aesthetics toxin market estimated at USD 3bn in 2025A, with mid-single-digit projected CAGR over 2026–2030 and mid-single-digit penetration for premium brands.

• US strategy centers on strategic accounts, a lean sales network, medical affairs, clinical credibility, and K-aesthetics positioning; direct-channel launch began in July.

• Strategic-account approach combines centralized contracting with CEO engagement and injector-focused clinical support; the model is designed for shorter deal cycles and higher impact per deal.

• After 11 weeks in the US, more than 30% of strategic-account targets were activated, with more than 50% of activated accounts purchasing; pipeline accounts represent over 500 clinic locations.

• Hybrid-to-CSO transition is intended to improve customer-data access, revenue transparency, pricing and commercial control, brand consistency, and medical-affairs coordination.

Portfolio expansion

• Planned 2027 US portfolio expansion supports Letybo and K-aesthetics positioning, including OPULUXE V topical skin booster, professionally dispensed Korean skincare, and WELLAGE retail skincare.

• Broader portfolio pipeline includes CellREDM ECM injectable, Jellatech human collagen, The Chaeum Signature HA filler, and multiple business-development deals in progress.